1
|
Makimoto H, Gerguri S, Hartl S, Kluge S, Clasen L, Bejinariu A, Brinkmeyer C, Schmidt J, Kelm M. Wide antral circumferential re-ablation in case of recurrent atrial fibrillation despite of prior pulmonary vein isolation increases freedom from atrial tachyarrhythmias. Europace 2022. [DOI: 10.1093/europace/euac053.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Despite repeated pulmonary vein isolation (re-PVI) due to recurrent atrial fibrillation (AF) after PVI has been a standard procedure, the detailed ablation strategy in case of re-PVI remains disputable.
Objective
The aim of this study was to assess the efficacy of re-PVI using wide antral circumferential ablation (WACA) supported by high density mapping (HDM) for recurrent AF after PVI as compared to simple repeated PVI supported by circular mapping catheter.
Methods
Consecutive patients with recurrent AF after PVI were prospectively enrolled in this study, who underwent left atrial HDM and subsequently WACA antral (re-)isolation ("Re-WACA" group). The historical controls with re-PVI between 2016 and 2018 using circular mapping catheter, but without HDM were also enrolled ("control group"). These control patients underwent re-PVI with gap ablation at the pulmonary vein ostium. Primary endpoint was defined as any recurrence and ECG documentation of atrial tachyarrhythmias (AT) including AF or atrial tachycardias over 30 seconds. The patients were routinely followed up for 1 year with at least twice annual holter-monitoring.
Results
In total, 116 patients were enrolled in this study (Re-WACA group [N=56, 68±10 years], control group [N=58, 65±10 years]). There were no significant differences in clinical characteristics including the number of previous left atrial ablation procedures between two groups. In all 56 patients with Re-WACA, residual PV antral potentials were demonstrated (100%), whereas 7 patients (13%) showed no electrical potentials inside any PVs. During a mean follow-up period of 402±71 days, 6 out of 56 Re-WACA patients (11%) and 18 out of 58 controls (31%) experienced AT recurrences. Kaplan-Meier analysis demonstrated that the patients who underwent Re-WACA showed significantly lower AT recurrence after the index Re-PVI procedure as compared to the controls (log-rank, P = 0.010). Multivariate Cox regression showed that Re-WACA was an independent predictor of freedom from AT recurrence (hazard ratio = 0.39; 95% confidence-interval 0.16-0.93; P=0.034). The number of previous PVI procedures predicted AT recurrence during follow-up (hazard ratio = 2.35; 95% confidence-interval 1.20-4.46; P=0.010).
Conclusions
Residual pulmonary vein antral potential in patients with recurrent AF after previously performed PVI is a frequent finding. These antral potentials can be easily visualized by HDM. Repeated isolation of wide PV antrum (Re-WACA) is an effective strategy to reduce further AF recurrence as compared to conventional re-PVI without left atrial HDM.
Collapse
Affiliation(s)
- H Makimoto
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - S Gerguri
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - S Hartl
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - S Kluge
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - L Clasen
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - A Bejinariu
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - C Brinkmeyer
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - J Schmidt
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - M Kelm
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| |
Collapse
|
2
|
Makimoto H, Shiraga T, Kohlmann B, Magnisali CE, Schenk R, Gerguri S, Motoyama N, Clasen L, Bejinariu A, Schmidt J, Brinkmeyer C, Westenfeld R, Zeus T, Kelm M. On-device artificial intelligence: mobile solution for detecting severe aortic valve stenosis based on heart sounds. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aortic stenosis is still one of the major causes of sudden cardiac death in the elderly. Noninvasive screening for severe aortic valve stenosis (AS) may result in early cardiac diagnostic leading to an appropriate and timely medical intervention.
Purpose
The aims of this study were 1) to develop an artificial intelligence to detect severe AS based on heart sounds and 2) to build an application to screen patients using electronic stethoscope and smartphones, which will provide an efficient diagnostic workflow for screening as a complementary tool in daily clinical practice.
Methods
We enrolled 100 patients diagnosed with severe AS and 200 patients without severe AS (no echocardiographic sign of AS [n=100], mild AS [n=50], moderate AS [n=50]). The heart sounds were recorded in 4000 Hz waveform audio format at the following 3 sites of each patient; the 2nd intercostal right sternal border, the Erb's area and the apex. Each record was divided into multiple data of 4 seconds duration, which built 10800 sound records in total. We developed multiple convolutional neural networks (CNN) designed to recognize severe AS in heart sounds according to the recorded 3 sites. We adopted a stratified 4-fold cross-validation method by which the CNN was trained with 60% of the whole data, validated with 20% data and tested with the remaining 20% data not used during training and validation. As performance metrics we adopted the accuracy, F1 value and the area under the curve (AUC) calculated as the average of all cross-validation folds.
For the smartphone application, we combined the best CNN-models from each recorded site for the best performance. Further 40 patients were newly enrolled for its clinical validation (no AS [n=10], mild AS [n=10], moderate AS [n=10], severe AS [n=10]).
Results
The accuracy, F1 value and AUC of each model were 88.9±5.7%, 0.888±0.006 and 0.953±0.008, respectively. The sensitivity and specificity were 87.9±2.2% and 89.9±2.4%. The recognition accuracy of moderate AS was significantly lower as compared to the other AS grades (moderate AS 74.1±6.1% vs no AS 98.0±1.4%, mild AS 97.6±1.2%, severe AS 87.9±2.2%, respectively, P<0.05).
Our smartphone application showed a sensitivity of 100% (10/10), a specificity of 73.3% (22/30), and an accuracy of 80.0% (32/40), which implicated a good utility for screening. In the detailed analysis of 8 mistaken decisions, these were highly affected by the presence of severe mitral or tricuspid valve regurgitation despite of non-severe AS (7/8 [87.5%]).
Conclusions
This study demonstrated the promising possibility of an end-to-end screening for severe aortic valve stenosis using an electronic stethoscope and a smartphone application. This technology may improve the efficacy of daily medicine particularly where the human resource is limited or support a remote medical consultation. Further investigations are necessary to increase accuracy.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Makimoto
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - T Shiraga
- Mitsubishi Electric Inc., Kamakura, Japan
| | - B Kohlmann
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - C.-E Magnisali
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - R Schenk
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - S Gerguri
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - N Motoyama
- Mitsubishi Electric Inc., Kamakura, Japan
| | - L Clasen
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - A Bejinariu
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - J Schmidt
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - C Brinkmeyer
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - R Westenfeld
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - T Zeus
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Dusseldorf, Germany
| | - M Kelm
- Heinrich Heine University, Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, CARID, Dusseldorf, Germany
| |
Collapse
|
3
|
Brockmeyer M, Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Heinen Y, Bejinariu A, Mueller P, Makimoto H, Kelm M, Wolff G. Uninterrupted direct oral anticoagulants and vitamin K antagonists during ablation for atrial fibrillation: an updated meta-analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Uninterrupted anticoagulation during catheter ablation of atrial fibrillation (CAAF) became standard of care after positive results of trials investigating vitamin K antagonists (VKA). Previous studies and meta-analyses of uninterrupted direct oral anticoagulants (DOAC) vs. VKA have given controversial results. We thus aimed to elucidate the risks and benefits of uninterrupted DOAC vs. VKA during CAAF in an updated meta-analysis of randomized controlled trials (RCTs).
Methods
Online databases were searched for RCTs comparing uninterrupted DOAC to VKA in patients undergoing CAAF until September 2019. Data from retrieved studies were analysed in a comprehensive meta-analysis. Primary safety outcome was major bleeding; primary efficacy outcome was stroke or transient ischemic attack (TIA). Secondary outcomes included a composite of major bleeding and stroke or TIA, minor bleeding, acute cerebral lesions on magnetic resonance imaging (ACL) and mortality.
Results
Six eligible RCTs comprising 2,369 patients were included. Pooled meta-analysis showed no significant differences in DOAC vs. VKA concerning the rates of major bleeding (2.2% vs. 3.8%; odds ratio (OR) 0.69, 95% confidence interval (CI) 0.30–1.56; p=0.37) and stroke or TIA (0.2% vs. 0.2%; OR 0.97, CI 0.20–4.72; p=0.97). There were no significant differences found in secondary outcomes (OR 0.73, p=0.49 for composite of major bleeding and stroke or TIA; OR 1.08, p=0.52 for minor bleeding; OR 1.12, p=0.59 for ACL; and OR=0.60, p=0.64 for all-cause mortality).
Conclusion
Our meta-analysis suggests that uninterrupted periprocedural anticoagulation with DOAC or VKA is characterized by a similar risk/benefit ratio in patients undergoing CAAF with comparable rates of major bleeding and stroke.
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Medical faculty of the Heinrich-Heine-University Düsseldorf, Germany
Collapse
Affiliation(s)
- M Brockmeyer
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - Y Lin
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - C Parco
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - A Karathanos
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - T Krieger
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - V Schulze
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - Y Heinen
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - A Bejinariu
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - P Mueller
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - H Makimoto
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - M Kelm
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| | - G Wolff
- Heinrich Heine University, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Dusseldorf, Germany
| |
Collapse
|